Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Veru Inc (VERU)

Veru Inc (VERU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference GlobeNewswire - Thu Jul 30, 7:30AM CDT

MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic...

VERU : 2.24 (+0.90%)
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss GlobeNewswire - Mon Jul 27, 7:10AM CDT

-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim analysis results on track for calendar Q1 ‘27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE)...

VERU : 2.24 (+0.90%)
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day GlobeNewswire - Tue Jul 7, 7:30AM CDT

MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic...

VERU : 2.24 (+0.90%)
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress GlobeNewswire - Wed May 13, 5:30AM CDT

--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for i nterim analysis first quarter calendar year 2027 — --Company to host conference...

VERU : 2.24 (+0.90%)
Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th GlobeNewswire - Wed May 6, 7:30AM CDT

MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and...

VERU : 2.24 (+0.90%)
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss GlobeNewswire - Mon Mar 9, 7:30AM CDT

-- The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients...

VERU : 2.24 (+0.90%)
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference GlobeNewswire - Thu Feb 19, 7:30AM CST

MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and...

VERU : 2.24 (+0.90%)
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress GlobeNewswire - Wed Feb 11, 5:30AM CST

-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast...

VERU : 2.24 (+0.90%)
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th GlobeNewswire - Wed Feb 4, 7:30AM CST

MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic...

VERU : 2.24 (+0.90%)
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress GlobeNewswire - Wed Dec 17, 2025

-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an...

VERU : 2.24 (+0.90%)

Barchart Exclusives

Wall Street Is Rewarding AI Results, Not Just AI Spending Barchart - Sun Aug 2, 4:19PM CDT
The market is buying CEO Andy Jassy's spending plan for Amazon. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.